Steven Mah
Stock Analyst at TD Cowen
(2.22)
# 2,855
Out of 5,090 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $32.30 | +79.57% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $25.46 | +21.76% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $9.25 | +1,197.30% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.71 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $17.64 | +138.10% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.56 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.95 | +412.82% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.58 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.83 | +1,047.54% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $244.55 | -36.62% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $27.79 | +403.78% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $2.39 | +2,075.73% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $128.96 | +221.81% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $27.76 | +800.58% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $32.30
Upside: +79.57%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $25.46
Upside: +21.76%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $9.25
Upside: +1,197.30%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.71
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $17.64
Upside: +138.10%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.56
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.95
Upside: +412.82%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.58
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.83
Upside: +1,047.54%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $244.55
Upside: -36.62%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $27.79
Upside: +403.78%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $2.39
Upside: +2,075.73%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $128.96
Upside: +221.81%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $27.76
Upside: +800.58%